Table 1.

Patient characteristics.

Patient number	1	2	3	4	5	6	7	8
Age (years)	67	34	48	32	34	53	54	29
Sex	Male	Female	Male	Male	Female	Male	Male	Female
Bevacizumab treatment at start of study	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
Treatment duration (weeks) at end of study	52	41	66	67	57	288	112	10
Treatment dosage	5 mg/kg 3-weekly	5 mg/kg 3-weekly	3.5 mg/kg 3-weekly	5 mg/kg 2-for 10 weeks; subsequently 2.5 mg/kg 2-weekly	7.5 mg/kg 2-weekly	5 mg/kg 3-for 276 weeks; subsequently 2.5 mg/kg 3-weekly	5 mg/kg 2-weekly for 32 weeks; subsequently 2.5 mg/kg 2-weekly	2.5 mg/kg 2-weekly
Treatment discontinuation	No	No	No	Yes	Yes	Yes	No	No
Follow up time (months)	8	9	7	8	8	26	12	15